ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

New York, New York–(Newsfile Corp. – December 21, 2024)– Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, inclusive of both dates (the “Class Period”), as significant January 17, 2025 Lead Plaintiff Deadline.

so what: If you purchase Humacyte securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Humacyte class action, go to https://rosenlegal.com/submit-form/?case_id=31305 or contact Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the court No later than January 17, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the lawsuit.

Why Rosen’s Law?:We encourage investors to select qualified advisors with a proven track record of success in leadership roles. Often, companies issuing notices do not have similar experience, resources, or any meaningful recognition from their peers. Many of these firms do not actually file securities class actions, but are merely brokers who refer clients or partner with the law firms that actually file the lawsuits. Be wise in choosing advisors. The Rosen Law Firm represents investors throughout the world, focusing its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever settlement of a securities class action lawsuit against a Chinese company at that time. Rosen Law Firm has been ranked #1 in the ISS Securities Class category an act (WA:) Services for a number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company raised more than $438 million for investors. In 2020, co-founder Lawrence Rosen was named by Law360 as a Titan in the Plaintiffs Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Case details: According to the lawsuit, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Humacyte’s Durham, North Carolina, facility failed to comply with good manufacturing practices, including quality assurance; microbial tests; (2) the Food and Drug Administration’s (“FDA”) review of the Biologics License Application (“BLA”) will be delayed while Humacyte addresses these deficiencies; (3) as a result, there was a significant risk to FDA approval of the acellular tissue engineering vessel (“ATEV”) for vascular trauma; and (4) as a result of the foregoing, Defendants’ positive statements about Humacyte’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims, investors suffered damages.

To join the Humacyte class action, go to https://rosenlegal.com/submit-form/?case_id=31305 or contact Phillip Kim, Esq. Toll free is 866-767-3653 or email case@rosenlegal.com for information about the class action.

No category is approved. Until the class is approved, you will not be represented by counsel unless you retain one. You can choose the lawyer of your choice. You can also remain an absent class member and do nothing at this point. An investor’s ability to participate in any potential future recovery is not dependent on serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https: //www.facebook.com/rosenlawfirm/.

Lawyer advertisement. Previous results do not guarantee a similar result.

—————————-

Contact information:

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234885